Back to News
Market Impact: 0.2
NeuroSense Therapeutics Ltd. Targets Revenues in 2027 Under Strategic Collaboration Agreement
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
NeuroSense Therapeutics signed a strategic collaboration agreement with an advisor to advance a revenue-generating supply of PrimeC, its lead ALS therapeutic candidate, to eligible patients through a licensed clinic. The announcement provides no figures on expected revenue, patient numbers, or timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
NRSN0.50
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Why is PagSeguro Digital stock plummeting 30% today?
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs